Home > Insider Trading > Filing (0001140361-14-037655)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1557883	Dermira Inc.	DERM	Pharmaceutical Preparations (2834)	273267680

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1014095	B Fred Craves	C/O Dermira, Inc. 2055 Woodside Road Redwood City CA 94061		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-10-08	3,356,337	$0.00	3,373,255	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2014-10-08	67,820	$16.00	3,441,075	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2014-10-08	63,958	$0.00	64,280	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2014-10-08	1,292	$16.00	65,572	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2014-10-08	2,337,590	$0.00	2,337,590	$0.00
Common Stock	Series A Preferred Stock	Disposition	2014-10-08	44,545	$0.00	44,545	$0.00
Common Stock	Series B Preferred Stock	Disposition	2014-10-08	643,066	$0.00	643,066	$0.00
Common Stock	Series B Preferred Stock	Disposition	2014-10-08	12,254	$0.00	12,254	$0.00
Common Stock	Series C Preferred Stock	Disposition	2014-10-08	375,681	$0.00	375,681	$0.00
Common Stock	Series C Preferred Stock	Disposition	2014-10-08	7,159	$0.00	7,159	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

In connection with the consummation of the Issuer's initial public offering on October 8, 2014, each share of Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration. All shares of Common Stock issued upon conversion were aggregated.
The securities are held directly by Bay City Capital Fund V, L.P. ("Fund V"). Dr. Craves disclaims beneficial ownership over the securities owned by Fund V, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in Bay City Capital LLC, which is the manager of Fund V's general partner, Bay City Capital Management V LLC.
The securities are held directly by Bay City Capital Fund V Co-Investment Fund, L.P. ("Co-Investment V"). Dr. Craves disclaims beneficial ownership over the securities owned by Co-Investment V, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in Bay City Capital LLC, which is the manager of Co-Investment V's general partner, Bay City Capital Management V LLC.
None.